Researchers Getting Smarter About Pairing Cancer Treatments
Anna Azvolinsky | Apr 1, 2018
Multidrug combinations lead to better results for cancer patients, but efficiently identifying them is proving difficult.
ISTOCK, LPETTET
FDA Approves First Marijuana-Derived Drug
FDA Approves First Marijuana-Derived Drug
As the CBD-based medication enters the market, the agency promises a crackdown on producers of cannabidiol products that make unproven claims.
As the CBD-based medication enters the market, the agency promises a crackdown on producers of cannabidiol products that make unproven claims.
Infographic: Cancer Drug Pairings
Anna Azvolinsky | Mar 31, 2018
Researchers use several different strategies to deliver a one-two punch.
Pfizer to Halt Alzheimer’s and Parkinson’s Drug Research
Jim Daley | Jan 7, 2018
The company’s recent effort to find new treatments for Alzheimer’s ended in disappointment.
Clinical Trial Reporting for Pharma-Sponsored Trials Shows Improvement
Diana Kwon | Dec 4, 2017
The Good Pharma Scorecard finds some big pharmaceutical companies are meeting legal standards for disclosing results—but many studies still go unreported.
RNA Interference Drug Excels in Clinical Trials to Treat Rare Disorder
Katarina Zimmer | Nov 3, 2017
If approved, patisiran will be the first RNAi therapeutic on the market.
Puerto Rico’s Hurricane Damage May Mean Drug Shortages
Ashley P. Taylor | Oct 11, 2017
Three weeks after Hurricane Maria hit the island, pharmaceutical plants are not back up to speed.
Opinion: Token Pharmacovigilance
Peter Doshi | May 23, 2017
A US government website for collecting reports of side effects associated with vaccines is broken. Why has no one noticed?
Johnson & Johnson to Acquire Swiss Biotech Firm for $30 Billion
Joshua A. Krisch | Jan 27, 2017
With its purchase of Actelion, Johnson & Johnson’s acquires experimental treatments for pulmonary arterial hypertension and several rare diseases.
Takeda to Buy Cancer Drug Maker Ariad for $5.2 Billion
Joshua A. Krisch | Jan 10, 2017
The pharma giant’s purchase of the US firm includes the acquisition of investigative cancer drugs.